| Cuba | Dominican Republic | Urban Peru | Rural Peru | Venezuela | Urban Mexico | Rural Mexico | Urban China | Rural China | Urban India | Rural India | Meta-analysed PR (95% CI) | Cochran's Q Higgins I 2 (95% CI) | PAPF median (range) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dementia | 9.46 (7.01-12.7) | 2.79 (2.11-3.68) | 6.76 (4.22-10.83) | 8.05 (2.93-22.1) | 4.21 (3.05-5.82) | 4.55 (3.06-6.75) | 3.58 (2.28-5.64) | 3.60 (2.60-4.9) | 5.35 (3.09-9.29) | 9.29 (3.72-23.2) | 2.87 (1.83-4.51) | 4.49 (3.98-5.07) | Q = 48.69 I2 = 79% | 34% (23-59) |
PAPF | 59% | 27% | 47% | 38% | 28% | 34% | 23% | 29% | 42% | 45% | 24% | Â | (64-88) | Â |
Paralysis/weakness | 1.87 (1.36-2.57) | 3.77 (2.82-5.03) | 2.02 (1.08-3.77) | 4.94 (1.63-14.9) | 1.13 (0.69-1.83) | 1.95 (1.13-3.37) | 3.40 (2.04-5.67) | 3.01 (1.89-4.79) | 13.27 (7.24-24.3) | 1.76 (0.22-13.9) | 2.90 (1.33-6.30) | 2.76 (2.38-3.20) | Q = 53.42 I2 = 81% | 9% (1-46) |
PAPF | 6% | 20% | 9% | 6% | 2% | 5% | 10% | 20% | 46% | 1% | 12% | Â | (68-89) | Â |
Stroke | 1.78 (1.36-2.33) | 1.27 (0.9-1.76) | 2.40 (1.43-4.03) | 3.01 (0.69-13.0) | 2.04 (1.41-2.95) | 1.92 (1.19-3.11) | 2.60 (1.62-4.17) | 1.31 (0.84-2.1) | 1.23 (0.59-2.57) | 3.86 (1.40-10.6) | 2.87 (1.13-7.33) | 1.78 (1.55-2.05) | Q = 15.10 I2 = 34% | 8% (2-17) |
PAPF | 10% | 5% | 17% | 7% | 11% | 8% | 13% | 7% | 2% | 10% | 6% | Â | (0-67) | Â |
Depression | 1.56 (1.08-2.24) | 2.79 (2.11-3.68) | 2.06 (1.35-3.15) | 5.25 (1.51-18.2) | 2.30 (1.43-3.69) | 0.93 (0.47-1.83) | 2.55 (1.52-4.27) | 1.00 (0.41-2.43) | 1.11 (0.61-2.02) | 2.57 (0.89-7.42) | 1.84 (1.03-3.29) | 1.70 (1.46-1.98) | Q = 15.63 I2 = 36% | 8% (0-27) |
PAPF | 3% | 27% | 7% | 16% | 8% | 0 | 8% | 0 | 1% | 10% | 10% | Â | (0-69) | Â |
Eyesight problems | 1.21 (0.97-1.50) | 1.40 (1.12-1.84) | 1.20 (0.82-1.75) | 0.72 (0.30-1.74) | 0.95 (0.70-1.29) | 1.36 (0.96-1.94) | 0.92 (0.59-1.45) | 1.18 (0.85-1.64) | 1.79 (0.94-3.39) | 2.06 (0.46-9.13) | 1.12 (0.70-1.80) | 1.20 (1.08-1.34) | Q = 9.37 I2 = 0 (0-60) | 6% (0-16) |
PAPF | 7% | 16% | 7% | 0 | 0 | 11% | 0 | 3% | 6% | 7% | 3% | Â | Â | Â |
Arthritis/rheumatism | 1.18 (0.93-1.50) | 0.93 (0.72-1.20) | 1.29 (0.89-1.88) | 0.53 (0.11-2.50) | 1.87 (0.85-1.65) | 1.32 (0.85-2.04) | 0.87 (0.56-1.37) | 1.50 (1.07-2.10) | 0.71 (0.15-3.28) | 1.05 (0.42-2.59) | 1.07 (0.66-1.74) | 1.13 (1.01-1.27) | Q = 8.73 I2 = 0 (0-60) | 4% (0-6) |
PAPF | 4% | 0 | 5% | 0 | 5% | 5% | 0 | 6% | 0 | 0 | 4% | Â | Â | Â |
Stomach/intestine problems | 0.86 (0.62-1.18) | 1.10 (0.82-1.48) | 1.01 (0.67-1.54) | 3.71 (1.13-12.2) | 0.72 (0.50-1.04) | 1.10 (0.69-1.76) | 1.98 (1.29-3.05) | 1.12 (0.72-1.74) | 4.22 (1.08-16.4) | NC | 1.39 (0.74-2.59) | 1.09 (0.95-1.25) | Q = 23.16 I 2 = 61% (22-81) | 1.5% (0-16) |
PAPF | 0 | 2% | 0 | 11% | 0 | 1% | 16% | 0 | 4% | Â | 2% | Â | Â | Â |
Hearing difficulty | 1.07 (0.82-1.39) | 1.32 (0.99-1.75) | 0.95 (0.65-1.38) | 1.31 (0.40-4.28) | 1.10 (0.75-1.59) | 0.98 (0.66-1.46) | 0.83 (0.52-1.34) | 1.04 (0.75-1.46) | 0.97 (0.52-1.80) | NC | 1.09 (0.66-1.80) | 1.06 (0.92-1.21) | Q = 4.38 I 2 = 0 (0-62) | 1% (0-5) |
PAPF | 1% | 5% | 0 | 4% | 2% | 0 | 0 | 1% | 0 | Â | 2% | Â | Â | Â |
Difficulty breathing | 1.17 (0.73-1.89 | 0.91 (0.63-1.33) | 1.39 (0.72-2.68) | 0.46 (0.12-1.65) | 1.22 (0.78-1.91) | 1.47 (0.70-3.11) | 1.04 (0.46-2.34) | 1.51 (0.93-2.46) | 1.45 (0.39-5.36) | 0.75 (0.12-4.43) | 1.47 (0.83-2.60) | 1.18 (0.98-1.41) | Q = 6.42 I 2 = 0 (0-60) | 1% (0-6) |
PAPF | 0 | 0 | 2% | 0 | 2% | 2% | 0 | 2% | 1% | 0 | 6% | Â | Â | Â |
Heart problems | 0.97 (0.66-1.43) | 1.34 (0.88-2.04) | 1.09 (0.60-1.99) | 2.29 (0.44-11.7) | 0.76 (0.45-1.27) | 1.03 (0.41-2.57) | 1.01 (0.28-3.59) | 1.41 (1.04-1.91) | 1.54 (0.56-4.18) | NC | NC | 1.17 (0.98-1.39) | Q = 6.51 I 2 = 0 (0-65) | 0 (0-9) |
PAPF | 0 | 2% | 0 | 4% | 0 | 0 | 0 | 9% | 1% | Â | Â | Â | Â | Â |
Faint/blackout | 1.13 (0.69-1.83) | 0.90 (0.53-1.53) | 1.09 (0.45-2.59) | 0.12 (0.01-1.31) | 1.46 (0.86-2.47) | 1.95 (0.35-10.6) | 0.89 (0.33-2.37) | 1.04 (0.61-1.77) | 0.51 (0.19-1.38) | 0.46 (0.03-7.24) | 1.78 (1.04-3.05) | 1.11 (0.90-1.37) | Q = 12.01 I 2 = 17% | 0 (0-11) |
PAPF | 0 | 0 | 0 | 0 | 3% | 0 | 0 | 0 | 0 | 0 | 11% | Â | (0-57) | Â |
COPD†| 0.88 (0.51-1.50) | 0.86 (0.55-1.33) | 0.58 (0.32-1.06) | 1.10 (0.35-3.47) | 1.14 (0.75-1.73) | 0.58 (0.27-1.27) | 1.49 (0.76-2.90) | 2.11 (1.42-3.2) | 1.04 (0.46-2.37) | NC | 0.86 (0.41-1.81) | 1.08 (0.91-1.30) | Q = 20.63 I 2 = 56% | 0 (0-4) |
PAPF | 0 | 0 | 0 | 0 | 1% | 0 | 4% | 4% | 0 | Â | 0 | Â | (12-78) | Â |
Skin disorders | 0.84 (0.51-1.40) | 2.57 (1.63-4.03) | 1.11 (0.69-1.81) | 0.26 (0.06-1.05) | 0.99 (0.64-1.53) | 0.47 (0.14-1.58) | 1.10 (0.60-2.00) | 0.38 (0.18-0.79) | NC | NC | 0.84 (0.33-2.14) | 1.05 (0.86-1.29) | Q = 28.73 I 2 = 72% | 0 (0-4) |
PAPF | 0 | 4% | 1% | 0 | 0 | 0 | 0 | 0 | Â | Â | 0 | Â | (45-86) | Â |
Infarction/Angina‡ | 1.01 (0.77-1.33) | 1.80 (1.13-2.88) | 0.80 (0.43-1.50) | 1.09 (0.26-4.40) | 1.26 (0.72-2.21) | 1.37 (0.53-3.54) | 0.58 (0.07-4.31) | 0.66 (0.43-1.1) | NC | 0.87 (0.10-7.08) | 0.46 (0.09-2.25) | 1.02 (0.85-1.21) | Q = 12.41 I 2 = 28% | 0 (0-3) |
PAPF | 0 | 3% | 0 | 0 | 2% | 1% | 0 | 0 | Â | 0 | 0 | Â | (0-65) | Â |
Persistent cough | 0.85 (0.40-1.76) | 0.89 (0.62-1.28) | 1.04 (0.63-1.73) | 2.30 (0.72-7.32) | 0.89 (0.56-1.39) | 0.94 (0.51-1.72) | 0.52 (0.17-1.54) | 0.77 (0.47-1.25) | NC | NC | 1.06 (0.52-2.12) | 0.94 (0.79-1.13) | Q = 5.24 I 2 = 0 (0-65) | 0 (0-2) |
PAPF | 0 | 0 | 0 | 2% | 0 | 0 | 0 | 0 | Â | Â | 0 | Â | Â | Â |
Hypertension | 0.79 (0.64-0.99) | 0.74 (0.57-0.96) | 1.01 (0.73-1.38) | 1.79 (0.71-4.51) | 0.97 (0.69-1.37) | 0.86 (0.60-1.23) | 1.47 (0.99-2.16) | 1.03 (0.77-1.4) | 1.48 (0.83-2.64) | 1.31 (0.59-2.88) | 0.66 (0.41-1.05) | 0.92 (0.83-1.02) | Q = 18.51 I 2 = 46% | 0 (0-23) |
PAPF | 0 | 0 | 0 | 21% | 0 | 0 | 20% | 2% | 23% | 15% | 0 | Â | (0-73) | Â |
TOTAL PAPF | 62.4% | 48.4% | 63.8% | 63.8% | 40.1% | 45.0% | 58.0% | 54.0% | 74.2% | 61.2% | 47.2% | Â | Â | Â |